Aptitude announced on Sept. 16, 2026, that the U.S. Food and Drug Administration granted 510(k) clearance for its next-generation Metrix COVID Test, a step that moves the product into traditional clearance for COVID-19 tests. The company said the test is its first FDA 510(k) clearance and that Metrix products remain broadly available during the respiratory season.
The next-generation test delivers about 3-fold greater analytical sensitivity than the original EUA-authorized product and returns results 30% faster. Aptitude said development of the test was supported by the Biomedical Advanced Research and Development Authority, while its next-generation Metrix COVID/Flu Test remains under FDA review for 510(k) clearance.
JP Wang on Metrix
JP Wang, Aptitude’s co-CEO, said the clearance does not end the work. “We're continually developing Metrix to make it better,” he said. “FDA clearance is an important step, not a stopping point.” He added, “We continue to push the Metrix platform forward with faster tests, better performance, simpler operations, and a broader menu for our growing customer base.”
That pipeline matters because Aptitude said the Metrix platform has been adopted by hundreds of clinics over the past year and was built for decentralized healthcare settings, especially urgent care. The company also said Metrix is FDA-cleared for both over-the-counter and professional use in CLIA-waived settings, giving clinics and other users a cleared path even as the portfolio shifts away from EUA status.
Scott Ferguson on expansion
Scott Ferguson, Aptitude’s co-CEO, said, “The opportunity is much larger than replacing existing molecular systems,” and added, “By removing the economic and operational barriers that have historically limited molecular testing, Metrix can bring molecular diagnostics into healthcare settings where it previously wasn't practical.”
Aptitude said the respiratory lineup is still moving forward on multiple fronts. Additional Metrix products targeting RSV, Strep and sexually transmitted infections are in late-stage development or under FDA review, and the company does not anticipate disruption to Metrix product availability during the upcoming respiratory season.
Metrix through December 2026
The transition has a deadline. The COVID-19 EUA declarations for medical devices are scheduled to terminate on Dec. 26, 2026, and Aptitude said previously distributed Metrix EUA-authorized products may continue to be used through their labeled expiration dates. For customers using Metrix now, the practical result is a cleared next-generation COVID test alongside older authorized stock that can still be used until it expires.
How much the 3-fold higher analytical sensitivity changes real-world detection in clinics and at home is not spelled out, but Aptitude’s filing points in one direction: faster results, broader clearance and a product line being moved ahead of the EUA framework before the December deadline arrives.
